HOME >> MEDICINE >> NEWS
New protease inhibitor held HIV at undetectable levels for four years

A study from The Feinberg School of Medicine has shown that the protease inhibitor lopinavir/ritonavir (Kaletra) suppressed HIV to undetectable levels and was well tolerated through four years of treatment in patients who had not previously received antiretroviral therapy.

To date in the Kaletra study, none of the patients has developed resistance to Kaletra or other protease inhibitors. Kaletra is thus far the only protease inhibitor for which resistance has not been observed in patients receiving it as an initial therapy.

Robert L. Murphy, M.D., professor of medicine at the Feinberg School and director of HIV/AIDS clinical research at Northwestern University, presented results of the study today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.

"Maintaining antiviral suppression to undetectable levels over the long term is crucial to patients' success," Murphy said.

"Drugs such as Kaletra, which have demonstrated high rates of viral suppression over several years, remain important options for initial therapy. Viral suppression helps prolong the time to development of resistance, which is an important cause of treatment failure," Murphy said.

In this ongoing phase II study, 100 patients who had not previously received antiretroviral therapy were given one of three doses of Kaletra in addition to the nucleoside analogues stavudine and lamivudine.

After 48 weeks, therapy for all patients was converted to the same dose of Kaletra with stavudine and lamivudine. Of the original group of patients, 72 remained in the study through four years; seven of the 28 patients who discontinued therapy did so because of adverse events attributed to Kaletra. All 72 patients maintained an undetectable HIV viral load of less than 400 copies per milliliter, and their CD4 counts increased consistently from the beginning of the study over the four-year period (mean increase of 416 cells per cubic millimeter).

Ka
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
27-Sep-2002


Page: 1 2

Related medicine news :

1. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
2. HIV-1 protease inhibitors: Effective against malaria?
3. FDA approves new HIV protease inhibitor, Lexiva (TM)
4. Pharmacokinetic data presented at ICAAC on investigational HIV protease inhibitor 433908 (908)
5. Molecules inhibit HIV protease, could lead to new line of attack against AIDS
6. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave
7. Two studies compare triple nucleoside therapy Ziagen® + Combivir® with protease inhibitorplus Combivir® regimens in therapy-naive patients
8. COX-2 inhibitors associated with blood pressure elevation
9. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
10. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
11. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
Cached News: